Fosamprenavir Main Page

Medical Advocates
Fosamprenavir (Lexiva/GW433908)

Main Page

New and Noteworthy

Journal Data

Conference Data

FDA Updates
Guidelines

Pediatric Data
Perinatal Data

Protease Inhibitors: General Data

Manufacture's Information
Lexiva December 2007 Revised Label

ARV Drugs Main Page Main New/Newsworthy Home Page

This web page is best viewed by using INTERNET EXPLORER
Last Update: August 06, 2008
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

New and Noteworthy

August 2008

Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment
in 82 therapy-nayive patients with HIV-1 infection.
Calza L, Manfredi R, Pocaterra D, Chiodo F. Int J STD AIDS. 2008 Aug;19(8):541-4.

July 2008

A WEEK IN REVIEW FEATURED REPORT
Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration
with fosamprenavir-ritonavir in opioid-dependent subjects.
Cao YJ, Smith PF, Wire MB, Lou Y, et al Pharmacotherapy. 2008 Jul;28(7):863-74.

FDA Updates

FDA Approves SNDA for Lexiva with a new daily dosing indication
US FDA October 12, 2007
New Oral Formulation of Lexiva. (fosamprenavir calcium) Approved
FDA June 14, 2007

Lexiva (fosamprenavir calcium) Tablets Prescribing Information Updates
FDA November 2006

Lexiva (fosamprenavir calcium) Tablets Patient Package Insert Updates
FDA November 2006

FDA Approves Updated Labeling for LEXIVA
Vertex November 15, 2005

The Food and Drug Administration (FDA) approved LEXIVA (Fosamprenavir calcium)
FDA October 20, 2003,

Pediatric Indications

USPHS Pediatric Antiretroviral Drug Information
US Treatment Guidelines

Conference Reports, Abstracts and Posters

Safety and Antiviral Activity of Fosamprenavir/Ritonavir Once Daily Regimens in HIV-infected
Pediatric Subjects Ages 2 to 18 Years (48-Week Interim Data, Study APV20003)
E Chadwick, W Borkowsky, C Fortuny, et al
(14 CROI)
Abstract

Safety and Antiviral Activity of Fosamprenavir-containing Regimens in HIV-infected 2- to
18-Year-Old Pediatric Subjects (Interim Data, Study APV29005)
C Cunningham, A Freedman, S Read, et al
(14 CROI)
Abstract

Perinatal Data

Guidelines

United States
Internet Documents

FULL TEXT PDF DOCUMENT
Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs
in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce
Perinatal HIV Transmission in the United States.
Perinatal HIV Guidelines Working Group.
November 2, 2007
Guidelines

FULL TEXT PDF DOCUMENT
Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy
Perinatal HIV Guidelines Working Group.
November 2, 2007
Guidelines

ARV Drugs Main Page Main New/Newsworthy Home Page

Fosamprenavir